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Abstract
Background
Methods for identifying physiologically relevant T-cell epitopes are critically important for development of
vaccines and the design of therapeutic proteins. As the number of proteins that are being evaluated for putative immunogenicity expands, rapid and accurate tools are in great demand. Several methods to identify
T-cell epitopes have been developed, the most recent of which is a cell free system consisting of a minimal
set of proteases incubated with HLA DRB1*0101, HLA-DM and whole antigen. Isolation and sequencing of
the HLA bound peptides using mass spectrometry allows for the prospective identification of immunodominant T-cell epitopes.
Results
We present here, a comparison of this cell free in vitro antigen processing system to an immunoinformatics
approach using the EpiMatrix algorithm. Our comparison reveals that in addition to identifying a similar set
of epitopes to the cell-free system, the immunoinformatics approach prospectively identifies more HLADRB1*0101 epitopes and can simultaneously analyze multiple HLA alleles.
Conclusions
Although the cell-free system incorporates antigen processing and MHC binding, the immunoinformatics
approach identifies many validated epitopes with a very high degree of accuracy and can be performed
much faster with far fewer resources.

Background
Methods for the prospective identification of physiologically relevant T-cell epitopes are critically important for
development of vaccines and for the design of therapeutic proteins. A cell free system (CFS) for prospectively
identifying T-cell epitopes from whole antigens was recently described and applied to the identification of influenza epitopes [1]. As described by Hartman et al. in their
publication, CFS epitope mapping was performed by preincubating whole antigens with HLA-DRB1*0101 and
HLA-DM, and then exposing the mixture of antigen and
HLA DR/DM to a minimal set of proteases, followed by
isolation and sequencing of the HLA-bound peptides
using mass spectrometry. The CFS was initially validated
using two model antigens (HA1 from influenza A/
Texas/1/77 and type II collagen) as positive controls and
then applied prospectively for the discovery of new HLA
-DRB1*0101 immunodominant epitopes from a recombinant liver-stage antigen of malaria falciparum (LSANRC) and HA1 from H5N1 influenza (Viet Nam).
The publication of the CFS method provided an opportunity for comparing a purely immunoinformatics approach
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based entirely on MHC binding affinity (EpiMatrix) to an
in vitro system that involves both antigen processing and
presentation [2]. We hypothesized that predicted MHC
binding (as performed in silico) would provide results
that were at least equivalent to the more laborious CFS
approach. As the identification of T cell epitopes using
the CFS approach. requires a significant amount of laboratory effort, reagents, and specific expertise in the use of
MALDI mass-spectrometry, the immunoinformatics approach might, in addition, offer significant time and cost
savings. As is described here, our detailed comparison
reveals that the immunoinformatics method correctly
identified four of the six epitopes identified by the CFS
method, at lower cost and with greater time efficiency,
and, in addition, identified other potential epitopes that
appear to have been missed by the CFS. Neither of the
two CFS epitopes that were missed by EpiMatrix were
validated in follow up assays. In the brief report below,
we provide a detailed comparison of the in silico approach using EpiMatrix and the CFS approach, in terms
of epitopes identified and the relative speed, effort required and cost of the two methods.

Results
CFS reductionist method
The CFS approach to finding immunodominant epitopes,
as published in reference 1, is described here for comparison with the EpiMatrix method. The cell free system
(CFS) is restricted to evaluations of a single HLA at a
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time. The assay requires combining a minimal set of
components for antigen processing (full length antigen,
human MHC Class II HLA-DRB1*0101, HLA-DM, and
Cathepsins S, B, and H) under both endosomal and lysosomal conditions. Hartman et al. describe the application of the CFS method to four proteins: (1) an artificial
construct of influenza H1N1 (A/PR/8/34) HA with a single, well-known DR1-restricted epitope (A/Texas/1/77
HA306-318) appended to the C-terminus; (2) Collagen type
II; (3) influenza H5N1 (A/Vietnam/1203/2004) HA and
(4) Liver stage malaria antigen. The resulting peptideDR1 complexes were isolated by immunoprecipitation
and the bound peptides were eluted under acidic conditions. These eluted peptides were then analyzed on a matrix-assisted laser desorption ionization (MALDI) mass
spectrometer.
Results for the CFS method were obtained using a single
allele (HLA-DRB1*0101) [1]. The eluted epitopes were
validated in vitro using T cell proliferation, cytokine induction, tetramer staining, or some combination of the
three following immunization of HLA-DRB1*0101 mice
with the whole protein antigen.
For example, recombinant HA1 (rHA1), engineered to
include a published epitope, was incubated in the cell
free system. After isolating HLA DRB1*0101 complexes, the genetically-linked A/Texas/1/77 known immunodominant epitope and only one other peptide (A/
PR/8/34 HA298-317) were eluted from peptide-DR1 complexes. T cell proliferation assays using peripheral blood
mononuclear cells (PBMC) obtained from HLA
DRB*0101 transgenic mice immunized with rHA1
showed a strong dose dependent response to the A/
Texas/1/77 single epitope identified by the cell free assay
and a weaker but still significant response to the A/
PR/8/34 peptide. The sum of proliferative responses (ex
vivo) to these two epitopes approached the magnitude of
the response to whole rHA1.
As a second example, bovine type II collagen (CII) was
used to test the epitope identification system. CII is a
major component of cartilage and is the main suspected
auto-antigen in rheumatoid arthritis in DR1+ individuals
[4]. A core DR1 restricted immunodominant epitope,
CII282-289, has been identified in CII in mouse studies.
Following enzymatic digestion and incubation in the
CFS, one peptide was eluted, CII273-305, as well as variants of that peptide that share the same core epitope. Proliferation studies performed with T cells from CIIimmunized mice validated the eluted CII273-305 epitope.
The CFS was also used to prospectively identify immunodominant DR1 epitopes from HA1 protein of influenza
A/Vietnam/1203/2004 (H5N1) and LSA-NRC, a recombinant modified version of a protein expressed exclusively in malaria-infected hepatocytes at a preerythrocytic stage, which was designed as a vaccine against
preerythrocytic stage malaria. Several new epitopes
(Figure 1) were identified in these previously unmapped
proteins and subsequently validated in T cell assays following immunization of HLA-DR1 transgenic mice with
the whole antigen in CFA.

Figure 1 - EpiMatrix prospectively identifies more potential epitopes
than the CFS.
Epitopes identified by the CFS are labelled C, epitopes discovered by
Immunoinformatics are labelled I and epitopes discovered by both are
labelled I/C; the rank in the HLA DR1 EpiMatrix analysis for the antigen is
indicated by the number 1-5; note that only one epitope from influenza A
Texas was used (recombinantly fused to the PR protein) rather than the
whole protein and therefore this single epitope is given the first rank (I/CTex1).

Immunoinformatics method
The sequences of the four antigens evaluated in the CFS
were obtained from GenBank and then analyzed using
EpiMatrix [EpiVax, Providence USA]. Standard criteria
(EpiMatrix score in top 5% of scores on a Z scale) were
used for epitope identification [2]. A list of the EpiMatrix
-predicted HLA DRB1*0101 epitopes was created and
compared to the epitopes identified by the CFS. EpiMatrix prospectively identified four of the six epitopes that
were identified by the CFS (67%), and one epitope from
each of the antigens; I/C-CII3, I/C-PR1, I/C-Tex1, and I/
C-LSA2 (Table 1). These epitopes are shown at the intersection of the Venn diagram in Figure 1 and labelled I/C
to denote that they were identified by both the Immunoinformatics (I) and the CFS (C) approaches.
All four I/C epitopes scored among the top 5 HLA
DRB1*0101 EpiMatrix scores for the antigens (the EpiMatrix rank is indicated by the numerical suffix in Table
1 and Figure 1). Both of the “C” epitopes, which were
discovered by the CFS but not by EpiMatrix, scored
within the top 10% of EpiMatrix scores, which is below
the top 5% cut-off that would normally be used for the
selection of T cell epitopes by EpiMatrix analysis. We
note that one of these epitopes, selected by the CFS (CVN45) has been reported to be HLA DRB1*0401- and
HLA DRB1*1101-restricted according to IEDB, but not
HLA DRB1*0101-restricted. Consistent with the IEDBreported findings, DRB1*0401 and DRB1*1101 EpiMatrix scores for this epitope are in the top 1% of predicted
binders. The second epitope identified by the CFS and
not by EpiMatrix (C-LSA11) fell just below the EpiMatrix cut-off for a positive score (1.58, rather than 1.64,
see Methods).
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Table 1 - Epitope Comparison
Summary of epitopes identified by EpiMatrix and the CFS. In the case of I/C-PR1, I/
C-Tex1, and C-VN45, multiple overlapping peptides were eluted in the CFS;
those peptides sharing the same core 9-mer
identified by EpiMatrix are considered one
epitope. Variable flanking resides are
indicated in grey text. Refer to Figure 1 for
nomenclature and annotation.

As compared to the CFS, the EpiMatrix immunoinformatics approach identified many more prospective epitopes for each of the antigens. Performing the analysis as
described here, a total of 13 epitopes were identified
based on their HLA DRB1*0101 score: these included
the three highest-scoring epitopes for each of four antigens that were evaluated by the CFS and the one highscoring HLA DRB1*0101 epitope from A/Texas (only
one published epitope was included in the rHA protein
tested in the CFS). Of these 13 epitopes, eight (62%)
were previously confirmed as human T cell epitopes,
according to IEDB; validation is not yet recorded the
remaining five epitopes.
Detailed comparison of CFS and EpiMatrix results
Epitope sequences identified by both the CFS and EpiMatrix method were cross-referenced against the Immune Epitope Database (IEDB) of published T cell epitopes and MHC ligands using the substring parameter.
Further, all T cell responses and MHC binding results
available on IEDB were compiled for each input antigen.
If IEDB is taken as the reference standard for validation
of epitopes predicted by either method, EpiMatrix prospectively identified five more „validated‟ epitopes that
the CFS method did not identify. CFS identified two epitopes that were not identified by EpiMatrix, and although
these are published in IEDB, they have been published
for alternative alleles. If more stringent criteria are applied, (restriction by HLA DRB1*0101 and publication
in IEDB), EpiMatrix correctly identified three of the
three (100%) HLA DRB1*0101-restricted epitopes. This
significant reduction is due in part to the limited HLArestriction references available on IEDB; of the four test
antigens, only H5N1 Vietnam had references qualified as
HLA-DRB1*0101-restricted. As we will discuss in
greater detail below, the single HLA DRB1*0101restricted epitope prospectively identified by the CFS (I/
C-CII5), was only validated as a result of querying the
EpiMatrix-identified core.
Influenza PR antigen. The single PR epitope that was
identified by both the CFS and EpiMatrix, I/C-PR1, was
ranked first of all PR-derived HLA DRB1*0101 epitopes

by EpiMatrix, and was extracted from the same amino
acid locus (306-318) as the influenza HA epitope control
peptide (I/C-Tex1) that was fused to the A/PR/8/34 antigen. The two epitopes also identified by EpiMatrix have
high DRB1*0101 scores (I/C-PR1 and I/C-Tex1) and
contain an epitope bar (or EpiBar) [6,7], a feature that is
often present in promiscuous epitopes [5], and that has
been associated with immunogenicity in human studies
[8,9]. This important feature of promiscuous, immunogenic epitopes is not detectable using the CFS. EpiMatrix
also identified two additional epitopes in influenza A/
PR/8/34 HA (Table 1).
Influenza A Viet Nam. When the full length HA1 from
H5N1 A/Vietnam/1203/2004 was analyzed in the CFS,
two unique peptide species were identified; both shared
the same core sequence (C-VN45). The authors selected
the shorter of these two peptides (HA259-274) to test for
immunodominance in T cell proliferation assays, cytokine production assays, and tetramer staining assays.
EpiMatrix analysis shows that the shorter HA most likely
has a truncated terminal HLA DRB1*0101 HLA binding
motif. The peptide only has one EpiBar at the C-terminal
end of the sequence and the N-terminal end of the peptide, which is devoid of predicted HLA binding motifs,
would interfere with binding, in vitro, and with immunogenicity. The properly centered peptide would have been
identified prospectively using EpiMatrix.
Three other epitopes were predicted by EpiMatrix in the
same protein to be better HLA DRB1*0101 binders, but
they were not identified by the CFS. All three have been
experimentally validated and published; only one was
confirmed for HLA DRB1*0101. Based on the fact that
the third-ranked EpiMatrix epitope is published and
found to be an HLA DRB1*0101 epitope in IEDB, the
other two (ranked 1 and 2) are equally likely if not more
likely to be HLA DRB1*0101-restricted, however this
would have to be tested prospectively in T cell assays as
was done for the CFS epitopes.
Collagen. It is notable that the single collagen epitope (I/
C-CII5) identified by the CFS was also confirmed by
EpiMatrix. It was the 5th ranked peptide for HLA
DRB1*0101, which is not unexpected considering the
greater length of the CII sequence compared to other
proteins examined in the CFS. The peptide has a
Page 3 of 5
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maximum DR1 EpiMatrix score of 2.66, putting it in the
top 1% of peptides expected to bind to DR1, a rank that
would have normally led to selection by EpiMatrix. The
sequence of the CFS eluted peptide CII273-305 contains the
same epitope that is predicted by EpiMatrix, however its
sequence is elongated and the probable HLA binding
motif is almost obscured by the extended flanks that were
eluted with the core sequence. When queried against the
IEDB, the CFS-eluted sequence returned no results,
whereas the EpiMatrix-identified core sequence was published as a DRB1*0101-restriced epitope. In other words,
immunoinformatics analysis using EpiMatrix can rapidly
and accurately identify a core HLA binding epitope,
whereas the CFS does not. EpiMatrix identified three
additional epitopes in Cll that are likely to be immunogenic (ranked 1, 2, and 3). One was previously reported
in IEDB but not confirmed in HLA transgenic mice nor
in human T cell assays.
Malaria LSA. Finally, the single LSA epitope identified
by both the Immunoinformatics approach and the CFS
method contains a strong EpiMatrix-scoring peptide, and
was the only LSA epitope to be validated in T cell assays. The weaker LSA epitope (C-LSA11) was also identified by the immunoinformatics approach, but the EpiMatrix score was slightly below the normal cut off for
selection. Two additional epitopes, I-LSA1 and I-LSA3
were identified using EpiMatrix, of which one (I-LSA1)
is found in IEDB for an unreported Class II HLA allele.

Discussion
The CFS method described by Hartman et al. is a novel
approach for identification of T cell epitopes that involves a significant amount of effort, reagents, and
highly technical expertise in the use of MALDI massspectrometry. One advantage of CFS is that the method
could, in theory, be applied to additional antigens and
alleles for which immunoinformatics approaches do not
yet exist. In comparison to the immunoinformatics approach, EpiMatrix, it appears to be both time- and costintensive. Many of the same epitopes are identified using
the two approaches. Additionally, previously validated
epitopes are identified using EpiMatrix that appear to be
missed by the CFS (when comparing CFS and EpiMatrix
results with the IEDB database of published and validated epitopes), as are several epitopes that appear likely
to be immunogenic based on their rank and EpiMatrix
score. Thus antigen-processing as performed using the
CFS may have destroyed peptides that might otherwise
have been presented by DR1. Two epitopes were identified using the CFS that would not have been selected by
EpiMatrix. Neither of these epitopes would qualify as
high quality targets based on information obtained from
IEDB.
Epitopes identified using the CFS were not compared to
epitopes that have already been published. Instead, in
vivo methods were used to validate sequences. Epitopes
were considered to be validated if, following immunization of HLA-DRB1*0101 mice with whole antigen,

T cells were induced to proliferate, cytokine production
was increased, or tetramer-stained cells could be
detected, or some combination of the three. These methods are useful for validation regardless of the epitope
selection method – and have been used for the validation
of T cell epitopes identified using EpiMatrix (see references 6 and 9).
The CFS may provide some additional information on
epitopes that are processed (two were identified in the
CFS that were not identified using EpiMatrix) and may
have application to organisms with little to no information on peptide-MHC interactions. A much more extensive (and perhaps cost-prohibitive) comparison would
have to be performed, prospectively validating the epitopes discovered using EpiMatrix alongside epitopes
discovered using the CFS, before either method is proven
to be superior to the other. At the very least, they appear
to be somewhat complementary.
It should be mentioned that there are a range of epitope
prediction tools available, however each tool may provide slightly different results [3]. For example, when
analyzing the sequences from H5N1 Vietnam and rLSA1, both of which contain CFS-only epitopes, (Figure 1)
with NetMHCII [10], an alternative epitope prediction
tool, NetMHCII predicted the H5N1 Vietnam epitope but
the rLSA-1 epitope was still not predicted. NetMHCII
predicted similar epitopes to EpiMatrix for the proteins
included in this analysis (data not shown) with the best
scoring EpiMatrix epitopes centered within the sequences
all of the strong binders predicted by NetMHCII.
NetMHCII does not further delineate the optimal epitope
when using its default peptide length of 15 amino acids
(http://www.cbs.dtu.dk/services/NetMHCII/) .
Immunoinformatics provides a rapid means of analyzing
protein sequences for multiple HLA alleles at the same
time. EpiMatrix prospectively identified more HLADRB1*0101 epitopes than the CFS, of which almost all
are present in IEDB. In addition to providing an analysis
of multiple alleles at once (not just HLA DRB1*0101)
and highlighting promiscuous epitopes (data not shown,
references 2 and 3 provide examples), the immunoinformatics approach can be performed at a fraction of the
time and cost (one day, no reagents, versus multiple
weeks, technician time, in vitro reagents, and MALDI
mass spectrometer costs). Thus immunoinformatics approaches with algorithms such as EpiMatrix provide a
clear cost and time advantage over CFS.
As the number of proteins that are being evaluated for
putative immunogenicity expands, rapid, inexpensive and
accurate tools are in great demand. The time and effort
involved in prospectively identifying peptides from a
single protein for a single allele were not reported for this
study. Based on rough estimates for the costs, the immunoinformatics method can be performed in less than
1/20th of the time and for 1/100th of the cost of the cell
free method. If one is to compare the cost of equipment
that would be necessary for these two methods (a single
internet accessible computer vs. a fully functional lab
with mass spectrometry and protein production
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capabilities), this gap grows exponentially wider.

Conclusions
Adding antigen-processing to epitope selection in vitro
does not improve prospective class II antigen identification. In this comparison of two methods for T cell epitope identification, the in vitro antigen-processing and
MHC-elution method (CFS) obscured two of three externally validated, HLA-DRB1*0101-restricted epitopes,
whereas the immunoinformatics approach (EpiMatrix)
correctly identified all published epitopes restricted by
DRB1*0101, and prospectively identified many additional epitopes that have yet to be validated. While the
CFS approach may enable identification of epitopes from
MHC for which there is little to no published information, the advantages of the immunoinformatics method,
which include a very high degree of accuracy, high
throughput, rapidity, and low cost, are clear.
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Methods
Immunoinformatics
Proteins analyzed by EpiMatrix are parsed into 9-mers
that overlap each other by 8 amino acids. Each of these 9
-mers is then scored individually (and simultaneously)
for predicted binding affinity against a panel of eight
common Class II HLA alleles (DRB1*0101, *0301,
*0401, *0701, *0801, *1101, *1301, and *1501) that
collectively cover over 95% of the human population
[11]. EpiMatrix scores range from approximately -3 to
+3. Those 9-mer peptides that score 1.64 or above are
considered to be potential epitopes. The predictions have
been benchmarked against the „gold standard‟ set of published epitopes, performing as well or better than other
epitope mapping tools [3]. Typically, 5% of all nine-mer
frames in a given protein score above 1.64; these are considered to have a significant chance of binding to HLA
molecules with moderate to high affinity and to have a
significant chance of being presented on the surface of
APCs [3].
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